Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study critically reviewed recent evidence (2020–2025) on treatments like platelet-rich plasma, photobiomodulation, stem cells, and exosomes for androgenetic alopecia, finding emerging but limited efficacy data and emphasizing the need for standardized protocols to enhance transparency and patient safety.

This review discusses the potential of platelet-rich plasma and exosome-based therapies for treating various types of alopecia, highlighting their promise but noting the need for more research on standardization and efficacy.

This study found that combining PRP with concentrated growth factors was more effective than PRP alone in promoting hair regrowth for patients with androgenetic alopecia.

This study observed that Platelet Rich Plasma was significantly more effective than 5% Minoxidil for treating alopecia areata in terms of improving the Severity of Alopecia Tool score.

In this study, researchers found that autologous PRP injections, when used as an adjuvant treatment with topical minoxidil, did not provide a significant increase in hair density compared to placebo in men with androgenetic alopecia in northeastern India.

This review highlights the potential of nanotechnology for hair follicle regeneration, focusing on strategies such as hair cycle modulation, progenitor cell stimulation, and wound-induced hair neogenesis, while also discussing regulatory challenges that may affect the development of these innovative approaches.

This systematic review found an increased incidence of hair loss and telogen effluvium among COVID-19 patients and reported preliminary effectiveness of platelet-rich plasma, adipose-derived mesenchymal stem cells, and human follicle stem cells for treatment without major side effects.

Using micrografts with stem cells and platelet-rich plasma can safely and effectively help regrow hair.

This study found that combining platelet-rich plasma with microneedling or fractional CO2 laser therapy was more effective in treating postacne atrophic scars than using these therapies alone, also boosting patient satisfaction.

This review highlights that although advancements in alopecia areata treatments, such as Janus kinase inhibitors and combination therapies, show promise, further research is necessary to validate their long-term safety and efficacy.

This review found that while platelet-rich plasma shows potential benefits for hair restoration, there is a lack of standardized preparation and treatment protocols, necessitating further rigorous trials.

This study suggests that platelet-rich plasma is a safe and effective treatment for alopecia areata, showing superior treatment response compared to triamcinolone acetonide and placebo, with primarily minor side effects.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

This review discusses photobiomodulation as a potential treatment for hair loss, highlighting its safety and possible effectiveness but noting cost, protocol standardization, and expectation management as limitations; it reports no new clinical results.

This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.

This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.

This study found that preserving hair grafts in platelet-rich plasma before implantation significantly improved hair density, graft uptake, and hair thickness compared to saline preservation in hair transplantation patients.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

This study found that intrauterine PRP infusion is a safe and effective treatment for patients with refractory thin endometrium and implantation failures, with the improvement primarily driven by the angiogenic cytokines in PRP.

This study reported that alopecia areata following COVID-19 vaccination is rare, occurring mostly after the first dose and associated with several vaccine types, particularly Pfizer.

This study found that exosomes derived from human adipose stem cells significantly enhanced the proliferation and migration of dermal papilla cells compared to those from platelet-rich plasma, suggesting potential benefits for hair loss treatment.

This review discusses the role of cutaneous and intestinal microbiota in the development of alopecia areata, summarizing current literature without reporting new clinical results.

This pilot study found a correlation between individual genetic inflammation profiles and the effectiveness of PRP treatment for hair regeneration, with differences observed between male and female responses.

Intradermal PRP significantly improved melasma in dark skin, with lasting results and no relapse after 3 months.

This review discusses various treatments for hair loss, such as topical agents, oral minoxidil, and laser therapies, but reports no new clinical results; debates on issues like post-finasteride syndrome are also covered.

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

This review examines the use of microneedles for treating alopecia areata, highlighting their ability to enhance drug delivery through the skin by bypassing the outer barrier and promoting hair growth with minimal invasiveness.

This study observed that PRP treatment resulted in greater improvement in hair thickness and density in alopecia areata patients compared to LLLT, with benefits sustained over 12 weeks.

In this study, PRP combined with microneedling was found to be an effective treatment for patients with androgenetic alopecia who did not respond to minoxidil and finasteride, with the majority of participants experiencing very good results after a minimum of four sessions.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.